Adaptive Biotechnologies Corporation
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$15.49
Price-11.28%
-$1.97
1Y
Price
Market Cap
$2.364b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+18.0%
EBITDA Margin+10.2%
Net Profit Margin-8.0%
Free Cash Flow MarginRevenue
$252.754m
+41.2%
1y CAGR+12.7%
3y CAGR+14.6%
5y CAGREarnings
-$79.612m
+50.1%
1y CAGR+22.3%
3y CAGR+17.5%
5y CAGREPS
-$0.54
+50.0%
1y CAGR+8.3%
3y CAGR+14.1%
5y CAGRBook Value
$204.253m
$490.610m
Assets$286.357m
Liabilities$213.641m
DebtDebt to Assets
43.6%
-3.7x
Debt to EBITDAFree Cash Flow
-$62.935m
+36.4%
1y CAGR+31.3%
3y CAGR+28.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company